Open-Label Trial of Atomoxetine to Evaluate Academic Outcome in Children Ages 8-11 Years With Attention Deficit/Hyperactivity Disorder

NCT00191880 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention Deficit Hyperactivity Disorder

Interventions

DRUG: atomoxetine

Sponsor

Eli Lilly and Company